Xeris Pharmaceuticals, Inc. (XERS): Price and Financial Metrics
XERS Stock Summary
- Xeris Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 8.65% of US listed stocks.
- XERS's went public 1.47 years ago, making it older than merely 1.63% of listed US stocks we're tracking.
- XERS's price/sales ratio is 121.31; that's higher than the P/S ratio of 98.32% of US stocks.
- Stocks that are quantitatively similar to XERS, based on their financial statements, market capitalization, and price volatility, are KPTI, PZG, OCUL, XPL, and CLSN.
- XERS's SEC filings can be seen here. And to visit Xeris Pharmaceuticals Inc's official web site, go to www.xerispharma.com.
XERS Stock Price Chart More Charts
XERS Price/Volume Stats
Xeris Pharmaceuticals, Inc. (XERS) Company Bio
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company’s lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company’s preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.